| |
Baseline
|
6 months
|
p-value
|
|---|
|
Main medications
|
|
- Beta-blockers
|
100 (83%)
|
101 (84%)
| |
|
- ACE inhibitors
|
103 (85%)
|
104 (86%)
|
|
- Statins
|
110 (91%)
|
105 (87%)
|
|
- Antiplatelet therapy
|
120 (99%)
|
115 (95%)
|
|
Body mass index (kg.m−2)
|
25 ± 4
|
25 ± 4
| |
|
Heart rate (bpm)
|
66 ± 11
|
57 ± 8
|
< 0.001
|
|
BP parameters
|
|
Systolic BP (mmHg)
|
129 ± 21
|
130 ± 20
| |
|
Diastolic BP (mmHg)
|
75 ± 14
|
72 ± 11
|
|
Mean BP (mmHg)
|
93 ± 15
|
92 ± 13
|
|
Cardiac parameters
|
|
LV end-diastolic volume (mL.m−2)
|
92 ± 15
|
96 ± 18
|
0.006
|
|
LV ejection fraction (%)
|
42 ± 8
|
49 ± 9
|
< 0.001
|
|
Total MI area (% of LV)
|
22 ± 12
|
16 ± 11
|
< 0.001
|
|
Transmural MI - presence (%)
|
94 (78%)
|
55 (46%)
|
< 0.001
|
|
- area (% of LV)
|
16 ± 13
|
8 ± 11
|
< 0.001
|
|
MVO - presence (%)
|
59 (49%)
|
0 (0%)
|
< 0.001
|
|
- area (% of LV)
|
8 ± 11
|
0 ± 0
|
< 0.001
|
|
SV-derived parameters
|
|
SV (mL.m−2)
|
38 ± 8
|
47 ± 9
|
< 0.001
|
|
Cardiac index (L.min−1.m−2)
|
2.4 ± 0.4
|
2.6 ± 0.5
|
< 0.001
|
|
TPVR (mmHg.min.m2.L−1)
|
39 ± 11
|
36 ± 9
|
0.001
|
|
TAC (mL.m−2.mmHg−1)
|
0.74 ± 0.21
|
0.83 ± 0.22
|
< 0.001
|
|
Ea (mmHg.m2.mL−1)
|
2.6 ± 0.9
|
2.1 ± 0.6
|
< 0.001
|
|
Stroke Work (L.mmHg.m−2)
|
3.5 ± 0.9
|
4.3 ± 1.0
|
< 0.001
|
-
ACE angiotensin converting enzyme, BP blood pressure, Ea effective arterial elastance, LV left ventricular, MI myocardial infarction, MVO microvascular obstruction, SV stroke volume, TAC total arterial compliance, TPVR total peripheral vascular resistance
